Home treatment of patients with cancer-associated venous thromboembolism – An evaluation of daily practice.

Link to article at PubMed

Related Articles

Home treatment of patients with cancer-associated venous thromboembolism - An evaluation of daily practice.

Thromb Res. 2019 Nov 04;184:122-128

Authors: Hendriks SV, Huisman MV, Eikenboom JCJ, Fogteloo J, Gelderblom H, van der Meer FJM, Stenger WJE, Verschoor AJ, Versteeg HH, Klok FA

Abstract
BACKGROUND: Home treatment of cancer-associated venous thromboembolism (VTE) is challenging due to the high risk of adverse events. While home treatment is quite agreeable to cancer patients, studies evaluating the safety of VTE home treatment in this setting are largely unavailable.
METHODS: This was an observational study in patients with cancer-associated VTE. The main outcomes were the proportion of patients treated at home (hospital discharge <24 h after diagnosis) and the 3-month incidence of VTE-related adverse events (major bleeding, recurrent VTE and/or suspected VTE-related mortality) in patients managed in hospital versus at home.
RESULTS: A total of 183 outpatients were diagnosed with cancer-associated VTE: 69 had deep vein thrombosis (DVT) and 114 had pulmonary embolism (PE ± DVT). Of those, 120 (66%) were treated at home; this was 83% for patients with DVT and 55% for patients with PE (±DVT). The 3-month incidence of any VTE-related adverse event was 13% in those treated at home versus 19% in the hospitalized patients (HR 0.48; 95%CI 0.22-1.1), independent of initial presentation as PE or DVT. All-cause 3-month mortality occurred in 33 patients treated as inpatient (54%) compared to 29 patients treated at home (24%; crude HR 3.1 95%CI 1.9-5.0).
CONCLUSIONS: Two-third of patients with cancer-associated VTE - including PE - were selected to start anticoagulant treatment at home. Cancer-associated VTE is associated with high rates of VTE-related adverse events independent of initial in hospital or home treatment. However, home treatment may be a good option for selected patients with cancer-associated DVT or PE.

PMID: 31731069 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *